Peng Lunxi, Wu Yi-Long
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.
The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510000, China.
J Thorac Dis. 2018 May;10(Suppl 13):S1482-S1493. doi: 10.21037/jtd.2018.05.106.
As "Immunotherapy age" is coming, immune checkpoint inhibitors (CPI) therapies have shown favorable clinical benefits and low toxicity profiles in patients with advanced non-small cell lung cancer (NSCLC). While it is a pity that there is a little clear clinical trials evidence about immunotherapy among Asian population. Moreover, since there is an ethnic difference for targeted therapy, what about immunotherapy? Which factors may associate with ethnic differences from Caucasian population to Asiatic population? In this review, we supposed that the characteristics of the much higher proportion of EGFR mutation, hepatitis B virus infection and unexpected immune-related toxicity among Asian patients should be considered.
随着“免疫治疗时代”的来临，免疫检查点抑制剂（CPI）疗法在晚期非小细胞肺癌（NSCLC）患者中显示出良好的临床疗效和较低的毒性特征。然而，遗憾的是，关于亚洲人群免疫治疗的临床试验证据尚少。此外，鉴于靶向治疗存在种族差异，免疫治疗情况如何呢？从白种人群到亚洲人群，哪些因素可能与种族差异相关？在本综述中，我们认为应考虑亚洲患者中EGFR突变比例更高、乙型肝炎病毒感染以及意外的免疫相关毒性等特征。
